key: cord-0692257-pcok2jcf
authors: Peng, Kah-Whye; Carey, Timothy; Lech, Patrycja; Vandergaast, Rianna; Muñoz-Alía, Miguel Á.; Packiriswamy, Nandakumar; Gnanadurai, Clement; Krotova, Karina; Tesfay, Mulu; Ziegler, Christopher; Haselton, Michelle; Sevola, Kara; Lathrum, Chase; Reiter, Samantha; Narjari, Riya; Balakrishnan, Baskar; Suksanpaisan, Lukkana; Sakuma, Toshie; Recker, Jordan; Zhang, Lianwen; Waniger, Scott; Russell, Luke; Petro, Christopher D.; Kyratsous, Christos A.; Baum, Alina; Janecek, Jody L.; Lee, Rachael M.; Ramachandran, Sabarinathan; Graham, Melanie L.; Russell, Stephen J.
title: Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine
date: 2022-01-10
journal: Vaccine
DOI: 10.1016/j.vaccine.2021.12.063
sha: 591af560c6c8f1d8d46404c94fb48ec83dbbbc9f
doc_id: 692257
cord_uid: pcok2jcf

An orally active vaccine capable of boosting SARS-CoV-2 immune responses in previously infected or vaccinated individuals would help efforts to achieve and sustain herd immunity. Unlike mRNA-loaded lipid nanoparticles and recombinant replication-defective adenoviruses, replicating vesicular stomatitis viruses with SARS-CoV-2 spike glycoproteins (VSV-SARS2) were poorly immunogenic after intramuscular administration in clinical trials. Here, by G protein trans-complementation, we generated VSV-SARS2(+G) virions with expanded target cell tropism. Compared to parental VSV-SARS2, G-supplemented viruses were orally active in virus-naive and vaccine-primed cynomolgus macaques, powerfully boosting SARS-CoV-2 neutralizing antibody titers. Clinical testing of this oral VSV-SARS2(+G) vaccine is planned.

Control of the SARS-CoV-2 pandemic will depend in part upon the global deployment of effective vaccines [1] . However, all currently approved SARS-CoV-2 vaccines are administered via intramuscular injection which increases the cost and complexity of vaccination programs, contributes to vaccine hesitancy and fails to stimulate mucosal immunity [2, 3] . Also, protective antibody titers are known to wane after successful vaccination (or after natural infection), such that periodic booster immunizations will be needed to sustain immunity, particularly in vulnerable individuals, so long as the virus remains endemic in the human population [4] [5] [6] .

Since oral and nasal mucosal surfaces are the primary portal of entry for SARS-like coronaviruses, the induction of mucosal immunity (via secretory IgA) may be the best way to prevent the virus from ever getting a foothold in the upper airways, thereby eliminating the risk of asymptomatic infection and virus shedding in vaccinated individuals which could aid virus transmission [7] . Available data from previous studies suggests that mucosal protection can be achieved most readily via mucosal vaccination using an oral or intranasal delivery route [3] which has been exemplified in previously licensed vaccines (e.g. Rotarix® and oral polio vaccines). From a cost, convenience and simplicity perspective, the oral route is preferred over the intranasal route since it does not require the use of a specialized delivery device (e.g. nebulizer). Also, from a safety perspective oral delivery avoids the risk that a live viral vaccine administered intranasally might spread into the brain via the olfactory neurons which pass through the cribriform plate at the apex of the nasal cavity [8] . Finally, compared to available injectable vaccines, oral vaccines are much preferred by children and adolescents whose high prevalence of vaccine hesitancy is linked to fear of needles [2, 9] .

Here, to develop an orally active viral vaccine capable of expressing the immunogenic SARS-CoV-2 spike glycoprotein in oral mucosa, we exploited the known tropism of vesicular stomatitis virus (VSV). Vesicular stomatitis is a self-limited illness of cattle and other ungulate species characterized by blistering of the oral mucosa and hooves [10] . The disease is endemic in Central America and the Southern United States, and the causative agent is vesicular stomatitis virus (VSV), a mosquito borne Vesiculovirus belonging to the family Rhabdoviridae. Human exposures to VSV infected cattle lead to asymptomatic seroconversion or sometimes a brief febrile illness with associated oral blistering [10] . VSV seroprevalence is very low in the human population, even in endemic areas [11] . VSV is a bullet-shaped virus with a lipid envelope and a single stranded negative sense RNA genome of approximately 11kb, comprising five genes encoding nucleocapsid (N), phosphoprotein (P), matrix (M), glycoprotein (G) and polymerase (L) proteins.

Virus entry is mediated via the interaction of the viral G protein with the low density lipoprotein (LDL) receptor, ubiquitously expressed on mammalian cells [12] .

To generate an orally active VSV-SARS2(+G) vaccine we substituted the G cistron of an Indiana strain VSV genome with a codon-optimized sequence encoding the Wuhan strain SARS-CoV-2 spike glycoprotein (S) and amplified the recombinant virus on Vero cells transiently expressing the G protein (Fig. 1A) . To facilitate S protein incorporation and G-independent propagation of the recombinant VSV-SARS2 viruses, a 19 amino acid S protein cytoplasmic tail truncation was introduced into the S protein [13] . The virus rescued from this construct was able to propagate autonomously, albeit slowly, with characteristic syncytial cytopathic effect on A549 cells transduced with the ACE2 receptor, but not on parental A549 cells (Fig. 1B) . Autonomously replicating non-G-deleted VSVs encoding the SARS-CoV2 spike protein that were generated in parallel were found to replicate efficiently on ACE2 negative cells, but rapidly lost expression of the spike protein, primarily via point mutations in key upstream regulatory sequences (data not shown). The stably and autonomously replicating VSV-SARS2 virions were next propagated on ACE2 receptor positive Vero cells transfected with a VSV-G expression plasmid to transpseudotype them with the G protein, which is also known to drive more efficient virus budding [14] . G-protein incorporation led to an approximately 10-fold enhancement of the infectious titer of the VSV-SARS2(+G) virus preparations (titers of 2 x10 9 TCID 50 per ml were achieved for the G supplemented viruses versus maximum titer of 5.1 x 10 7 TCID 50 without G protein. In a parallel study, incorporating the SARS-CoV-2 spike coding sequences as an additional cistron (that is, without deletion of G) proved to be highly unstable since their replication was not dependent on the integrity of the SARS-CoV-2 spike.

Biochemical characterization of the recombinant virus particles confirmed the incorporation a partially cleaved S protein in pure VSV-SARS2 virions, and the co-incorporation of S and G proteins in the G-pseudotyped VSV-SARS2(+G) virions (Fig. 1C) . SARS-CoV2 S protein expression after infection with VSV-SARS2 or VSV-SARS2(+G) was confirmed by western blotting and/or flow cytometry of ACE2 negative baby hamster kidney cells (BHK) and ACE2 positive Vero cells after infection by the respective viruses ( Fig. 1C and D) . VSV-SARS2 virions were neutralized by a cocktail of monoclonal anti-S SARS-CoV-2 neutralizing antibodies, but not by anti-G antibodies, indicating that they enter cells exclusively via their displayed S protein (Fig.   1E ). In contrast, after treatment with anti-S or anti-G antibodies, G-pseudotyped VSV-SARS2(+G) virions retained 20% or 4% infectivity respectively but were more fully neutralized when the anti-S and anti-G antibodies were used in combination (Fig. 1E ).

To facilitate in vivo studies in non-human primates (NHP), and possible clinical translation, midscale preparations of the VSV-SARS2 and VSV-SARS2(+G) viruses were generated using adherent GMP-qualified Vero cells as the substrate. Crude viral supernatants from these production runs were clarified by centrifugation and filtration, treated with benzonase, and purified by tangential flow filtration prior to cryopreservation. Viral stocks were titrated post-thawing by TCID 50 assay on Vero cell monolayers, then characterized for S and G protein incorporation and endotoxin content.

Expression of ACE2 receptors is not prominent on primate myocytes [14] . However, based on a published report demonstrating protective immunity to SARS-CoV-2 in hamsters vaccinated by intramuscular administration of a G-deficient VSV-G-SARS-CoV-2 construct [15] , we tested our own G-deficient VSV-SARS2 construct by intramuscular (IM, 10 7 TCID 50 ) vaccination of six virus-naive cynomolgus macaques ( Fig. 2A) . Compared to unvaccinated control animals, all monkeys in this experimental group developed detectable anti-S antibody responses by 4 weeks after vaccination (Fig. 2 , B, C). However, the absolute magnitude of the anti-spike IgG and neutralizing antibody titers observed in these animals were very low relative to mean human convalescent titers [16] .In parallel with this intramuscular study, 10 mls of the virus (10 7 TCID 50 ) was administered into the oral cavity of animals (PO) under brief sedation. Immune responses to the oral application of the virus were not detected in any of the animals in this group (Fig. 2 , B, C). The conclusion of this preliminary study in cynomolgus macaques was that the G-deficient VSV-SARS2 virus was weakly immunogenic when administered by the intramuscular route and is minimally immunogenic by the oral route.

To determine whether G protein supplementation could enhance the potency of the recombinant VSV vaccine, we administered VSV-SARS2(+G) to a total of four virus-naive cynomolgus macaques, either by IM injection (n=2) or PO (n=2). Both IM vaccinated animals and one of the orally vaccinated animals rapidly generated high IgG and neutralizing antibody titers against the SARS-CoV-2 spike glycoprotein (Fig. 3, A, B) . Neutralizing antibody titers were well maintained with no significant decline in two of the three responding animals until the end of the study (six (Fig. 4D ). In addition, we have previously shown that the neutralizing antibody assay using the vesiculo-pseudovirus has good correlation (R=0.89, p < 0.0001) with the classical plaque reduction neutralizing titer PRNT assay using the BSL3 live SARS-CoV-2 virus [18] . Analysis of peripheral blood mononuclear cells revealed significant increases in S protein specific IFNγ-secreting T cells in these orally boosted animals, but not of IL4-secreting T cells in a ELISPOT assay (Fig. 4E) . Significantly, anti-G antibodies were not detected in any of the orally boosted animals (Fig. 4F ), suggesting that it may be possible to use the G-pseudotyped platform repeatedly in the same individual to boost immunity against diverse coronavirus spike glycoproteins. Analysis of buccal and bronchoalveolar lavage (BAL) fluid obtained at euthanasia from these orally boosted and control animals revealed a substantial increase in the level of spike specific IgA as an indicator of mucosal immunity (Fig. 4 

The tolerability of VSV-SARS2 and VSV-SARS2(+G) vaccines was examined in all NHPs via physical examination, behavioral observations, complete blood counts, and serum chemistries, with a complete necropsy at the end of the study. Body weights were stable with a gain trend and there were no significant changes in the serum C-reactive protein, an acute inflammation marker infection severity and vaccine identity [19] . Antibody titers have also been shown to fall quite rapidly over time with half-lives varying from 2.5 and 6 months, signifying 4-fold to 25-fold titer reductions in the first year [4, 6, 20] . Thus, while the appropriate timing of SARS-CoV-2 vaccine booster shots has not yet been determined for specific subgroups of individuals, booster vaccination will likely be an important part of the strategy for longer-term control of the pandemic.

Future studies comparing the efficacy of oral booster doses of VSV-SARS-CoV-2 and VSV-SARS2(G) in non-human primates would also be warranted after priming with currently approved vaccines.

Compared to currently approved mRNA and adenoviral vaccines which are administered by intramuscular injection, mucosal vaccination may offer a more reliable and durable defense against SARS-CoV-2 infection [3] . Mucosal surfaces in the nose and mouth provide the primary portal of entry for respiratory pathogens such as SARS-CoV-2 and are best protected by secretory polymeric IgA in mucus and saliva. Secretory polymeric IgA is efficiently induced by mucosal vaccines because they interact directly with mucosal associated lymphoid tissues such as the lingual and palatine tonsils which encircle the posterior outlet of the oral cavity. Oral mucosal vaccination may also overcome some of the logistical drawbacks of injectable vaccines such as the limited availability and high cost of vials, needles, syringes, and trained personnel, and the high prevalence of needle phobia in preadolescents, adolescents and college students. Comparing to intranasal vaccine delivery which has been successfully developed and deployed for influenza prevention [21] , oral delivery may be a preferred approach to avoid the risks (and costs) of live virus aerosolization and CNS exposure associated with intranasal delivery.

Interestingly, while it was generally accepted at the outset of the SARS-CoV-2 pandemic that protein, mRNA and nonreplicating adenoviral vaccines could be developed very rapidly, it was also argued that vaccines built on replicating viral platforms might prove to be more potent, potentially affording protection after a single dose. Based on the extraordinary success of VSV-EBOV, a G-substituted VSV encoding the Ebola surface glycoprotein, which fully protects against Ebola virus infection within 2 weeks after a single intramuscular shot [22] , it was predicted that a G-substituted VSV encoding the SARS-CoV-2 spike glycoprotein would be equally effective as an intramuscular vaccine to protect against COVID-19. However, in human trials the efficacy of this G-substituted construct, administered by intramuscular injection, fell short of expectations and induced suboptimal titers of neutralizing antibodies [23] . Our studies in cynomolgus macaques confirm the low immunogenicity of the VSV-SARS2 vaccine construct, but further extend the narrative by demonstrating the enormous promise of the same construct as an oral mucosal booster vaccine when modified to incorporate the VSV.G protein. We have therefore recently engineered a series of VSV-SARS2 constructs encoding the spike proteins of emerging SARS-CoV-2 variants.

G protein pseudotyping of a replication defective VSV encoding the SARS-CoV spike glycoprotein was shown previously to enhance the immunogenicity of the construct when administered to NHPs by IM injection, but oral administration was not attempted [24] .

Interestingly, another group recently exploited G protein trans-complementation as a way to restore the immunogenicity of a G-deleted VSV-derived vaccine for SARS-CoV-2 in ACE2 receptor negative mice [25] . VSV-eGFP-SARS-CoV-2, an autonomously replicating ACE2 receptor-dependent VSV which encodes the SARS2 spike glycoprotein and a GFP reporter gene was trans-complemented with "a small amount" of VSV-G protein, then used to vaccinate mice via the intraperitoneal route which resulted in robust, protective anti-spike antibody responses.

These investigators further demonstrated the feasibility of intranasal vaccination using the same construct, but without G protein supplementation, in mice that were transgenic for the ACE2 receptor [25] . Although not formally proven, we speculate that the superior immunogenicity of the G-supplemented virus preparation, both by IM and PO routes, reflects a higher efficiency of muscle cell and oral mucosal transduction due the virus-displayed G protein interacting with the LDL receptor on myocytes and oral mucosal epithelium. We further speculate that the high potency of the intramuscular VSV-EBOV vaccine is likely the consequence of a high abundance of Ebola virus receptors in muscle tissue leading to efficient transduction by the injected viral particles, and that conversely the inferior efficacy of the VSV-SARS2 vaccine in the absence of G protein supplementation, is the consequence of low muscle expression of ACE2, the primary receptor for the SARS-CoV-2 spike protein [14, 26] . However, we cannot rule out the possibility of an additional contribution due to an immune adjuvant effect of the G protein itself.

The absence of an immune response to the VSV G protein when the G-supplemented viruses were administered orally is an important feature of the VSV-SARS2(+G) system which will allow for the future generation and deployment of G-supplemented VSVs whose G cistron has been substituted for envelope glycoproteins from other coronaviruses (e.g. those causing the common cold), or from pathogenic viruses belonging to non-coronaviridae families. G-supplemented VSV particles may therefore eventually prove to be a versatile oral mucosal vaccine platform capable of addressing a range of respiratory pathogens.

Limitations of this study include the small number of animals used and that we did not address the IM route of administration for the G-pseudotyped VSV-SARS2 vaccine. Nevertheless, our study does show that the G-pseudotyped VSV-SARS2 vaccine is orally active as a booster in NHPs and therefore may have considerable relevance for the significant percentage of individuals who refuse vaccination due to needle phobia.

In summary, as a proof of concept, we utilized a relevant translational NHP model to demonstrate 

Full-length human codon-optimized SARS-CoV-2 Spike (S) glycoprotein (NC_045512.2) in pUC57 was obtained from GenScript (MC_0101081). The plasmid was used as a PCR template to generate a cDNA encoding SARS-CoV-2 spike with a deletion in the nucleotides encoding the Cterminal 19 amino acids (S-Δ19CT) and 5' MluI and 3' NheI restriction sites. To generate the viral genome, the amplified PCR product containing S-Δ19CT was cloned into pVSV in place of VSV-G using the MluI and NheI restriction sites (Fig. 1) . Plasmid was sequence verified and used for infectious virus rescue on BHK-21 cells as previously described [27] . VSV-G was co-transfected into the BHK-21 cells to facilitate rescue but was not present in subsequent passages of the virus. 

co-monolayers, which produce functional Renilla luciferase following virus-mediated cell fusion, were seeded at 610 4 cells per well in 96-well black-walled plates the day before assay.

Neutralizing antibody cocktails were prepared in OptiMEM as follows: α-SARS-CoV-2 spike cocktail (mAb10914 at 6 µg/mL combined with mAb10922 at 2 µg/mL, Genscript) [4] , α-VSV-G cocktail (mAbVSV-G 8G5F11, Absolute Antibody #Ab01401-2.3) at 2 µg/mL combined with mAb VSV-G IE9F9 (Absolute Antibody #Ab01402-2.0) at 10 µg/mL [28] , and α-SARS-CoV-2 Certified 25% Protein Primate Diet from Harlan Laboratories, and fruits or vegetables were provided twice daily and water was available ad libitum. The behavioral management program included social housing in pairs (except during bond breakdown or pending reintroduction), enrichment, and basic training. Environmental enrichment included human interaction and a variety of treats, toys, foraging puzzles, and sensory stimuli like music. Structural enrichment included perches, swings, and climbing apparatus. NHPs were trained prior to study for cooperation with routine husbandry tasks only which included targeting and shifting [30, 31] .

In experiment 1, eighteen adult males and females with the median age of 3.7 years (range 3.4 to 6.7 years) and median body weight of 4.8 kg (3.2 to 6.8kg) were stratified by sex and randomly assigned to control and vaccine groups (Fig. 2) . Animals received Sham control (N=6) at an equivalent volume to vaccinated animals, animals in vaccine groups received VSV-SARS2 at a dose of 10 7 TCID 50 PO (N=6) or 10 7 TCID 50 IM (N=6) on day 0. All 12 vaccinated animals received an oral dose of VSV-SARS2(+G) as an oral boost on day +42. In experiment 2, four demographically similar males with median age of 4.4 years (range 4.4 to 5.2 years) and median weight of 5.5kg (range 5.1 to 6.1 kg) were used (Fig. 3) . Animals received VSV-SARS2(+G) at a dose of 10 8 TCID 50 PO (N=2) or IM (N=2) on day 0. Intramuscular vaccines were administered with a needle and syringe without adjuvant or orally using an oral syringe and gently tipping the head slightly back to deliver under the tongue and into the cheek pouches, with gently swabbing around the mouth with a cotton swab during the 5 minute dwell to mimic swishing.

Clinical observations of animals were performed at least twice daily for general attitude, activity level, gait, posture, appearance, feces, urine and any signs of pain or distress.

Body weight was measured at least weekly. Animals were sedated for sham or test article administration, blood collection, and clinical exams using ketamine (5-15mg/kg IM) and midazolam was added (0.1-0.3mg/kg IM), if necessary, to extend sedation. All exams included weight and temperature measurements, complete examination of the oral mucosa, swabs, and blood sampling.

Blood was collected using a peripheral vein and standard catheter at qualification, baseline prior to vaccination, then post vaccination biweekly, weekly, monthly or bi-monthly based on phase for clinical pathology that included complete blood counts, blood chemistries, CRP, and coagulation profiles. At these same timepoints nasal, buccal, and rectal swabs and fresh stool were also collected. At selected timepoints, additional assessment of immune profile pre and post vaccination was performed that included neutralizing antibody response and CD4/CD8 T cell response and characterization of VSV viremia and viral shedding.

Study Termination. All animals were euthanized at the completion of study and a full necropsy was performed which included a full gross examination. Bronchial alveolar lavage (BAL) was performed at necropsy by insertion of tube into the trachea, past the third bifurcation, and subsequent installation of 5-10 ml of sterile saline. Manual suction was applied to retrieve the BAL sample. Harvested tissues were fixed for a minimum of 72 hours in 10% neutral-buffered formalin and then embedded in paraffin. These tissues were evaluated histologically for signs of pathology by a board-certified veterinary pathologist blinded to study group allocations. evaluating IgA from the buccal swabs, the raw OD450 (with subtraction of 630nm reference) was compared directly between swab preparations prepared from saline control animals with swab preparations prepared from animals that received the oral VSV-SARS2(+G) boost.

Vero-ACE2 cells were seeded at 10 4 

Buccal, rectal, and nasal swabs were cut and placed in 700 µL of OptiMEM containing antibiotics.

After a 1 min. vortex at maximum speed, swabs were snap frozen in liquid nitrogen and then thawed at room temperature. Samples were centrifuged at 12,000 x g for 5 minutes at 4 o C, then filtered through a 0.22 µm syringe filter. Testing of swab samples spiked with VSV-G-SARS- 

Tukey's multiple comparison test or a two-tailed unpaired Student's t test was conducted to compare differences between vaccine groups and the control group with Bonferroni correction applied to control the type I error rate for the comparisons. 

☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☒ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Stephen J Russell has patent pending to Vyriad & Regeneron. Vyriad, Imanis and Regeneron employees own stocks or stock options in their respective companies. Drs. Russell, Peng, Imanis, Vyriad, Regeneron have a financial interest in this research.

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

Understanding influenza vaccine perspectives and hesitancy in university students to promote increased vaccine uptake

Prospects for mucosal vaccine: shutting the door on SARS-CoV-2

IMMUNO-COV™ v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers

Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

As Plain as the Nose on Your Face: The Case for A Nasal (Mucosal) Route of Vaccine Administration for Covid-19 Disease Prevention

The Olfactory Bulb: An Immunosensory Effector Organ during Neurotropic Viral Infections

The number of injected same-day preschool vaccines relates to preadolescent needle fear and HPV uptake

Attenuated vesicular stomatitis viruses as vaccine vectors

LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus

Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus spike proteins

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

A single dose of recombinant VSV-G-spike vaccine provides protection against SARS-CoV-2 challenge

Rapidly Increasing SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced from Plasma Collected During the 2020 Pandemic

Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells

Development and validation of IMMUNO-COV: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2. bioRxiv

Evidence for antibody as a protective correlate for COVID-19 vaccines

Neutralizing antibody titres in SARS-CoV-2 infections

Live attenuated influenza vaccine

Fluenz): a review of its use in the prevention of seasonal influenza in children and adults

The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials

In a major setback, Merck to stop developing its two Covid-19 vaccines and focus on therapies

SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector

Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Neuroattenuation of Vesicular Stomatitis Virus through Picornaviral Internal Ribosome Entry Sites

The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. I. Analysis of neutralizing epitopes with monoclonal antibodies

Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals

Positive Reinforcement Training and Research

Successful implementation of cooperative handling eliminates the need for restraint in a complex non-human primate disease model

Measles virus spread and pathogenesis in genetically modified mice

Female and male Ifnartm-CD46Ge mice [32] received intra-peritoneally 5x10 5 TCID 50 virus particles or 5μg of SARS-CoV-2 spike protein (Cat.# V0589-V08B, Sino Biological) adjuvanted with aluminum (Cat.#vac-alu-250,InvivoGen) on day 0 and 21. On days 21 (before boost) and 41, blood was collected

:5,000, Cat.# 115-035-206, Jackson ImmunoResearch) secondary antibody. After final wash, plates were developed using 50μl of 1-Step Ultra TMB (3,3',5,5'-tetramethylbenzidine; brief, HEK293T cells seeded overnight were transfected with HDM-Hgpm2, HDM-tat1b, pRC-CMV-Rev1b, pHAGE-CMV-Luc2-IRES-ZsGreen-W and a codon-optimized SARS-CoV-2 spike encoding the D614G amino acid change. The culture media was changed to fresh media containing antibiotics 18h to 24h post-transfection. At 60h post-transfection, supernatants were harvested and passed through a 0.45μm filter. For pseudovirus neutralization assay, three-fold serially diluted serum samples were mixed with SARS-CoV-2-pseudotypedlentiviruses for 1 hours at 37 °C. And the mixture was added in quadruplicates to hACE-2-expressing HEK293T cells overnight

GraphPad Software

ELISpot Analysis Frozen PBMCs were used to evaluate IFNγ, IL-4 T cell responses in NHP and frozen splenocytes were used IFNγ T cell responses in murine samples. Individual overlapping SARS CoV-2 Spike peptides (BEI Resources, NIAID, NIH: Peptide Array

Peptides were used at 0.5ug/ml concentration per peptide to elicit IFNγ and/or IL-4 responses. For NHP samples, low-fluorescent PVDF membrane (Millipore, Bedford, MA, USA) plates were coated with IFNγ and IL-4 capture antibodies overnight. Previously frozen PBMCs from NHP were washed, resuspended in T cell media (RPMI 1640 media containing 25 mM HEPES, NEAA, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.05mM 2-mercaptoethanol supplemented with 10% (vol./vol.) heat-inactivated fetal bovine serum), counted and added to wells at 250,000 cells per well. SARS CoV2 Spike domain peptide pools

ELISpot assays were performed using the mouse IFN-gamma ELISpot kit (Cat.# EL485, R&D systems Briefly, 5×10 positive control, PMA/Ionomycin cell stimulation cocktail (Biolegend, USA) was used at 2.5μl/ml, and as negative control, splenocytes were stimulated with equivalent DMSO concentration (0.8%). Post 48-hour incubation, plates were developed in measured at various time points

Figure 4: Oral VSV-SARS2(+G) powerfully boosts the immune response in vaccine-primed cynomolgus macaques. (A) Experimental design. Animals received initial VSV-SARS2 vaccine by IM or PO routes, and at day 42, the IM vaccinated NHP received an oral boost of VSV-SARS2(+G). 4 NHP received the high dose of 10 9 TCID 50 and 2 NHP received the lower dose of 5x10 6 TCID 50 VSV-SARS2(+G) (B) IgG titers against spike. (C) Neutralizing antibody titers using the live SARS-CoV-2 spike VSV pseudovirus and (D) a lentiviral pseudovector displaying the spike protein. (E) IFN-gamma and IL-4 ELISPOT assay for spike antigen reactive T cells from peripheral

SARS(+G) virus, S=VSV-SARS2 virus (F) Anti-VSV.G IgG antibody titers in boosted animals

IgA titers in bronchoalveolar lavage fluid (BALF) and (H) buccal fluid of animals